Literature DB >> 26014607

Cardiopulmonary fitness is related to disease severity in multiple sclerosis.

Martin Heine1, Inez Wens2, Martin Langeskov-Christensen3, Olaf Verschuren4, Bert O Eijnde2, Gert Kwakkel5, Ulrik Dalgas3.   

Abstract

BACKGROUND: In persons with MS (pwMS), a lower cardiopulmonary fitness has been associated with a higher risk for secondary disorders, decreased functional capacity, symptom worsening and reduced health-related quality of life.
OBJECTIVE: To investigate the association between disease severity and cardiopulmonary fitness.
METHODS: Data from cardiopulmonary exercise tests, previously conducted in three different countries, were pooled. The association between disease severity (Expanded Disability Status Scale (EDSS)) and cardiopulmonary fitness (peak oxygen uptake (VO2peak)) was adjusted for age, sex and the country of origin.
RESULTS: The combined sample comprised 116 ambulant pwMS having a mean (± SD) EDSS score of 2.7 ± 1.3. There was a significant correlation (r = -0.418, p < .01) between VO2peak and EDSS. A multiple regression model (R(2) = 0.520, p < .01) was constructed to describe VO2peak (mL∙kg(-1)∙min(-1)); VO2peak = 36.622 - 5.433 (Sex (1=men)) - 0.124 (Age) - 2.082 (EDSS) + 2.737 (Belgium) + 8.674 (Denmark).
CONCLUSION: There was a significant association between disease severity and cardiopulmonary fitness. The close relation between cardiopulmonary fitness and chronic conditions associated with physical inactivity, suggest a progressive increase in risk of secondary health conditions in pwMS.
© The Author(s), 2015.

Entities:  

Keywords:  Expanded Disability Status Scale; Multiple sclerosis; aerobic capacity; cardiopulmonary fitness; comorbidity; exercise test

Mesh:

Year:  2015        PMID: 26014607     DOI: 10.1177/1352458515581437

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

Review 1.  Exploring Wellness Interventions in Progressive Multiple Sclerosis: an Evidence-Based Review.

Authors:  Myriam Venasse; Thomas Edwards; Lara A Pilutti
Journal:  Curr Treat Options Neurol       Date:  2018-04-10       Impact factor: 3.598

2.  Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.

Authors:  Martin Heine; Olaf Verschuren; Erwin Lj Hoogervorst; Erik van Munster; Hub Ga Hacking; Anne Visser-Meily; Jos Wr Twisk; Heleen Beckerman; Vincent de Groot; Gert Kwakkel
Journal:  Mult Scler       Date:  2017-05-22       Impact factor: 6.312

3.  Exercise intensity-dependent immunomodulatory effects on encephalomyelitis.

Authors:  Nina Fainstein; Reuven Tyk; Olga Touloumi; Roza Lagoudaki; Yehuda Goldberg; Oryan Agranyoni; Shiri Navon-Venezia; Abram Katz; Nikolaos Grigoriadis; Tamir Ben-Hur; Ofira Einstein
Journal:  Ann Clin Transl Neurol       Date:  2019-08-01       Impact factor: 4.511

4.  Exercise Physiology Impairments of Patients With Amyotrophic Lateral Sclerosis: Cardiopulmonary Exercise Testing Findings.

Authors:  Ji He; Jiayu Fu; Wei Zhao; Chuan Ren; Ping Liu; Lu Chen; Dan Li; Lequn Zhou; Lu Tang; Xiangyi Liu; Shan Ye; Xiaolu Liu; Yan Ma; Yixuan Zhang; Xinran Ma; Linjing Zhang; Gaoqi Zhang; Nan Li; Dongsheng Fan
Journal:  Front Physiol       Date:  2022-03-14       Impact factor: 4.566

Review 5.  Fitness, physical activity, and exercise in multiple sclerosis: a systematic review on current evidence for interactions with disease activity and progression.

Authors:  Sebastian Proschinger; Puya Kuhwand; Philipp Zimmer; Niklas Joisten; Annette Rademacher; David Walzik; Clemens Warnke
Journal:  J Neurol       Date:  2022-01-27       Impact factor: 6.682

6.  Altered muscle oxidative phenotype impairs exercise tolerance but does not improve after exercise training in multiple sclerosis.

Authors:  Jan Spaas; Richie P Goulding; Charly Keytsman; Lena Fonteyn; Jack van Horssen; Richard T Jaspers; Bert O Eijnde; Rob C I Wüst
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-08-04       Impact factor: 12.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.